首页 > 最新文献

Journal of the American Pharmacists Association最新文献

英文 中文
Megesterol acetate as an overlooked cause of hyperglycemia in end-stage renal disease: A case of polypharmacy 醋酸甲酯醇是终末期肾病患者高血糖的一个被忽视的原因:一个多药并用的病例。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-12 DOI: 10.1016/j.japh.2024.102248
John Aurora Jr., Theresa Zheng, Julieta Rossi Fortunati, Feyza Erenler

Background

This case report highlights an overlooked cause of hyperglycemia and risk of polypharmacy in a patient with end-stage renal disease (ESRD).

Case summary

A 75-year-old non-English speaking male with type 2 diabetes mellitus, hypertension, coronary artery disease status post percutaneous coronary intervention, and ESRD secondary to immunoglobulin G kappa nephropathy on nightly peritoneal dialysis reported a loss of appetite, decrease in weight, and an increase in symptoms of depression. As a result of these symptoms, his nephrologist initiated megestrol acetate (MA), an agent commonly used in ESRD to help stimulate appetite and improve weight. After starting MA, his blood glucose (BG) significantly worsened, due to its glucocorticoid properties. Basal insulin was started to manage his hyperglycemia, but there was minimal improvement in BG. As the patient was referred to the endocrinology clinical pharmacist for diabetes management, it was identified that his weight loss began after starting dulaglutide, which led to a weight loss of 11 kg (12.9%). The Naranjo algorithm was used, and he had a score of 6, which is a probable reaction. The patient’s endocrinology and nephrology teams agreed to discontinue MA and dulaglutide as they resulted in opposing effects on appetite and BG, as well as insulin glargine. The patient’s BG was tightly controlled off MA and his appetite, weight, and mood improved off dulaglutide.

Practice implications

This case report reflects the potential effects of polypharmacy in ESRD, resulting in poor patient outcomes and drug interactions. It is imperative that a comprehensive medication reconciliation is completed on all patients, especially for patients on dialysis. It is also important for healthcare professionals to be cognizant of medications that may exhibit glucocorticoid properties, which can cause hyperglycemia. Including a clinical pharmacist in the care team can assist with medication reconciliation, screening for drug interactions and polypharmacy, and optimizing chronic disease management.
目的:病例摘要:一位 75 岁的非英语国家男性患者患有 T2DM、高血压、经皮冠状动脉介入治疗后冠状动脉疾病状态,以及继发于 IgG Kappa 肾病的 ESRD,每晚接受腹膜透析,他报告说食欲不振、体重下降,抑郁症状加重。由于出现了这些症状,他的肾病医生给他服用了醋酸甲地孕酮(MA),这是一种常用于 ESRD 的药物,有助于刺激食欲和改善体重。开始使用醋酸甲地孕酮后,由于其糖皮质激素的特性,他的血糖(BG)明显恶化。患者开始使用基础胰岛素控制高血糖,但血糖改善甚微。由于患者被转诊至内分泌科临床药剂师处接受糖尿病管理,因此发现他的体重在开始服用度拉鲁肽后开始下降,导致体重下降了 11 公斤(12.9%)。采用纳兰霍算法,他的评分为 6 分,属于可能的反应。患者的内分泌科和肾内科团队同意停用 MA 和度拉鲁肽,因为这两种药物对食欲和血糖以及格列美脲胰岛素的影响截然相反。停用 MA 后,患者的血糖得到了严格控制,而停用度拉鲁肽后,他的食欲、体重和情绪都得到了改善:本病例报告反映了在 ESRD 中使用多种药物的潜在影响,导致患者治疗效果不佳和药物相互作用。当务之急是对所有患者,尤其是透析患者进行全面的药物调节。同样重要的是,医护人员要认识到可能具有糖皮质激素特性的药物会导致高血糖。在护理团队中加入临床药剂师可协助进行药物协调、筛查药物相互作用和多重用药以及优化慢性病管理。
{"title":"Megesterol acetate as an overlooked cause of hyperglycemia in end-stage renal disease: A case of polypharmacy","authors":"John Aurora Jr.,&nbsp;Theresa Zheng,&nbsp;Julieta Rossi Fortunati,&nbsp;Feyza Erenler","doi":"10.1016/j.japh.2024.102248","DOIUrl":"10.1016/j.japh.2024.102248","url":null,"abstract":"<div><h3>Background</h3><div>This case report highlights an overlooked cause of hyperglycemia and risk of polypharmacy in a patient with end-stage renal disease (ESRD).</div></div><div><h3>Case summary</h3><div>A 75-year-old non-English speaking male with type 2 diabetes mellitus, hypertension, coronary artery disease status post percutaneous coronary intervention, and ESRD secondary to immunoglobulin G kappa nephropathy on nightly peritoneal dialysis reported a loss of appetite, decrease in weight, and an increase in symptoms of depression. As a result of these symptoms, his nephrologist initiated megestrol acetate (MA), an agent commonly used in ESRD to help stimulate appetite and improve weight. After starting MA, his blood glucose (BG) significantly worsened, due to its glucocorticoid properties. Basal insulin was started to manage his hyperglycemia, but there was minimal improvement in BG. As the patient was referred to the endocrinology clinical pharmacist for diabetes management, it was identified that his weight loss began after starting dulaglutide, which led to a weight loss of 11 kg (12.9%). The Naranjo algorithm was used, and he had a score of 6, which is a probable reaction. The patient’s endocrinology and nephrology teams agreed to discontinue MA and dulaglutide as they resulted in opposing effects on appetite and BG, as well as insulin glargine. The patient’s BG was tightly controlled off MA and his appetite, weight, and mood improved off dulaglutide.</div></div><div><h3>Practice implications</h3><div>This case report reflects the potential effects of polypharmacy in ESRD, resulting in poor patient outcomes and drug interactions. It is imperative that a comprehensive medication reconciliation is completed on all patients, especially for patients on dialysis. It is also important for healthcare professionals to be cognizant of medications that may exhibit glucocorticoid properties, which can cause hyperglycemia. Including a clinical pharmacist in the care team can assist with medication reconciliation, screening for drug interactions and polypharmacy, and optimizing chronic disease management.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"64 6","pages":"Article 102248"},"PeriodicalIF":2.5,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of a pharmacist-led multidisciplinary approach to the treatment of latent tuberculosis in refugee patients in the primary care setting 评估以药剂师为主导的多学科方法,以治疗基层医疗机构中难民患者的潜伏肺结核。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-12 DOI: 10.1016/j.japh.2024.102246
Sara Farooqi, Lara Horvath, Eddie Miljkovic, Ayan Mohamed, Sha-Phawn Williams

Background

Treatment of latent tuberculosis infection (LTBI) is essential for refugee patients who have been relocated to the United States to prevent progression to active infection.

Objective

This study aimed to determine the effectiveness of a multidisciplinary team approach, embedded within a primary care clinic, to treatment of LTBI in newly resettled refugee patients compared with a local health department.

Methods

This was a single-center, retrospective chart review of newly resettled refugee patients 18-89 years old with a diagnosis of LTBI. The primary objective was completion rate of LTBI therapy within 1 year of resettlement. Secondary objectives were incidence of adverse events, regimen switches, and adherence rate.

Results

A total of 58 patients were included in the study: 14 individuals through the multidisciplinary clinic and 44 individuals with the local health department. Completion of therapy within 1 year of resettlement was seen in 71.4% of patients (n = 10) in the multidisciplinary clinic compared with 72.7% (n = 32) at the health department. There were 7 patients who underwent a regimen switch, all of whom were in the health department arm. Adverse effects occurred in 14.2% of patients in the multidisciplinary clinic and 15.9% of patients in the health department arm. Treatment adherence was 98.6% in the multidisciplinary clinic and 90.5% in the local health department arm.

Conclusion

Use of a multidisciplinary team was successful in completion of LTBI treatment in refugee patients, helping to alleviate barriers to treatment completion by ensuring adherence and close follow-up.
背景:治疗潜伏肺结核感染(LTBI)对于被重新安置到美国的难民患者来说至关重要,以防止发展为活动性感染:目的:与当地卫生部门相比,确定在初级保健诊所内采用多学科团队方法治疗新近安置的难民患者潜伏肺结核感染的效果:这是一项单中心、回顾性病历审查,审查对象为年龄在18-89岁之间、被诊断患有LTBI的新近定居难民患者。首要目标是重新安置后一年内完成LTBI治疗的比率。次要目标是不良事件发生率、治疗方案转换和坚持率:共有 58 名患者参与了研究,其中 14 人通过多学科诊所接受治疗,44 人通过当地卫生部门接受治疗。71.4%(10 人)的多学科诊所患者在安置后 1 年内完成了治疗,而卫生部门的这一比例为 72.7%(32 人)。有 7 名患者更换了治疗方案,全部来自卫生部门。14.2%的多学科诊所患者和15.9%的卫生部门治疗组患者出现了不良反应。多学科诊所的治疗依从性为98.6%,当地卫生部门的治疗依从性为90.5%:结论:利用多学科团队成功地完成了对难民患者的LTBI治疗,通过确保坚持治疗和密切随访,帮助减轻了完成治疗的障碍。
{"title":"Evaluation of a pharmacist-led multidisciplinary approach to the treatment of latent tuberculosis in refugee patients in the primary care setting","authors":"Sara Farooqi,&nbsp;Lara Horvath,&nbsp;Eddie Miljkovic,&nbsp;Ayan Mohamed,&nbsp;Sha-Phawn Williams","doi":"10.1016/j.japh.2024.102246","DOIUrl":"10.1016/j.japh.2024.102246","url":null,"abstract":"<div><h3>Background</h3><div>Treatment of latent tuberculosis infection (LTBI) is essential for refugee patients who have been relocated to the United States to prevent progression to active infection.</div></div><div><h3>Objective</h3><div>This study aimed to determine the effectiveness of a multidisciplinary team approach, embedded within a primary care clinic, to treatment of LTBI in newly resettled refugee patients compared with a local health department.</div></div><div><h3>Methods</h3><div>This was a single-center, retrospective chart review of newly resettled refugee patients 18-89 years old with a diagnosis of LTBI. The primary objective was completion rate of LTBI therapy within 1 year of resettlement. Secondary objectives were incidence of adverse events, regimen switches, and adherence rate.</div></div><div><h3>Results</h3><div>A total of 58 patients were included in the study: 14 individuals through the multidisciplinary clinic and 44 individuals with the local health department. Completion of therapy within 1 year of resettlement was seen in 71.4% of patients (n = 10) in the multidisciplinary clinic compared with 72.7% (n = 32) at the health department. There were 7 patients who underwent a regimen switch, all of whom were in the health department arm. Adverse effects occurred in 14.2% of patients in the multidisciplinary clinic and 15.9% of patients in the health department arm. Treatment adherence was 98.6% in the multidisciplinary clinic and 90.5% in the local health department arm.</div></div><div><h3>Conclusion</h3><div>Use of a multidisciplinary team was successful in completion of LTBI treatment in refugee patients, helping to alleviate barriers to treatment completion by ensuring adherence and close follow-up.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"64 6","pages":"Article 102246"},"PeriodicalIF":2.5,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of a drug deactivation system for safe disposal of opioids after ambulatory surgery 评估用于在非住院手术后安全处置阿片类药物的药物失活系统。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-11 DOI: 10.1016/j.japh.2024.102247
William C. Oles, Eric S. Vilsmark, Carly Magoon, Kate Weathersbee, Francis Melaragni, Antje M. Barreveld

Background

Prescription opioids are commonly prescribed postoperatively and increase the risk of diversion or misuse when left unused and accessible. Despite awareness of the risks associated with unused opioids, harm reduction strategies like safe storage and drug take-back events may be limited by inconvenience and patient-specific barriers to access.

Objective

To evaluate a quality improvement project designed to facilitate at-home disposal of unused opioids after day surgery.

Methods

An observational, prospective quality improvement project was conducted in patients undergoing elective outpatient surgery at Newton-Wellesley Hospital from December 2019 to June 2020. Upon discharge, eligible patients received a Deterra drug disposal packet which deactivates unused medication. Follow-up surveys assessed packet use and reasons for nonuse 1 to 2 weeks after surgery.

Results

One hundred six participants received a disposal packet and responded to the survey. Among the 67 respondents with unused medication, 30% used the packet. Women were more likely to use the packet than men (predicted probability 30.2% vs. 10.4%, P = 0.033), and patients aged 18–25 were more likely to use the packet than those aged 26–40 (40.0% vs. 9.5%, P = 0.049). The most common reasons for packet nonuse included procrastination, holding onto prescriptions in case of future pain, and waiting to dispose of multiple medications.

Conclusion

The majority of patients surveyed had unused opioids 1 to 2 weeks after surgery, and approximately 1 in 3 patients with unused doses utilized the disposal packet. Common reasons for nonuse included procrastination and concerns about needing future medication for pain. Going forward, safe drug disposal efforts may emphasize improved patient education, partial prescription fill options, or alert systems to remind patients to safely dispose of unused medication.
背景:阿片类处方药通常是术后处方,如果未使用且容易获取,则会增加转移或滥用的风险。尽管人们意识到了未使用的阿片类药物所带来的风险,但安全储存和药物回收活动等减少危害的策略可能会因使用不便和患者特有的障碍而受到限制:评估一项旨在促进日间手术后未使用阿片类药物居家处置的质量改进项目:从 2019 年 12 月到 2020 年 6 月,在纽顿-韦尔斯利医院接受择期门诊手术的患者中开展了一项观察性、前瞻性质量改进项目。符合条件的患者在出院时会收到一份 Deterra® 药物处置包,该药物包能使未使用的药物失效。后续调查评估了药物包的使用情况以及术后一到两周未使用药物包的原因:结果:106 名参与者收到了药物处理包并回答了调查。在 67 位有未使用药物的受访者中,30% 的人使用了药包。女性比男性更有可能使用药包(预测概率为 30.2% 对 10.4%,p = .033),18-25 岁的患者比 26-40 岁的患者更有可能使用药包(40.0% 对 9.5%,p = .049)。不使用药包的最常见原因包括拖延、保留处方以防将来疼痛,以及等待处理多种药物:结论:接受调查的大多数患者在术后一到两周内都有未使用的阿片类药物,约三分之一的未使用患者使用了处置包。未使用阿片类药物的常见原因包括拖延和担心今后需要药物止痛。展望未来,安全药物处置工作可能会强调改进患者教育、部分处方填充选项或警报系统,以提醒患者安全处置未使用的药物。
{"title":"Evaluation of a drug deactivation system for safe disposal of opioids after ambulatory surgery","authors":"William C. Oles,&nbsp;Eric S. Vilsmark,&nbsp;Carly Magoon,&nbsp;Kate Weathersbee,&nbsp;Francis Melaragni,&nbsp;Antje M. Barreveld","doi":"10.1016/j.japh.2024.102247","DOIUrl":"10.1016/j.japh.2024.102247","url":null,"abstract":"<div><h3>Background</h3><div>Prescription opioids are commonly prescribed postoperatively and increase the risk of diversion or misuse when left unused and accessible. Despite awareness of the risks associated with unused opioids, harm reduction strategies like safe storage and drug take-back events may be limited by inconvenience and patient-specific barriers to access.</div></div><div><h3>Objective</h3><div>To evaluate a quality improvement project designed to facilitate at-home disposal of unused opioids after day surgery.</div></div><div><h3>Methods</h3><div>An observational, prospective quality improvement project was conducted in patients undergoing elective outpatient surgery at Newton-Wellesley Hospital from December 2019 to June 2020. Upon discharge, eligible patients received a Deterra drug disposal packet which deactivates unused medication. Follow-up surveys assessed packet use and reasons for nonuse 1 to 2 weeks after surgery.</div></div><div><h3>Results</h3><div>One hundred six participants received a disposal packet and responded to the survey. Among the 67 respondents with unused medication, 30% used the packet. Women were more likely to use the packet than men (predicted probability 30.2% vs. 10.4%, <em>P</em> = 0.033), and patients aged 18–25 were more likely to use the packet than those aged 26–40 (40.0% vs. 9.5%, <em>P</em> = 0.049). The most common reasons for packet nonuse included procrastination, holding onto prescriptions in case of future pain, and waiting to dispose of multiple medications.</div></div><div><h3>Conclusion</h3><div>The majority of patients surveyed had unused opioids 1 to 2 weeks after surgery, and approximately 1 in 3 patients with unused doses utilized the disposal packet. Common reasons for nonuse included procrastination and concerns about needing future medication for pain. Going forward, safe drug disposal efforts may emphasize improved patient education, partial prescription fill options, or alert systems to remind patients to safely dispose of unused medication.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"64 6","pages":"Article 102247"},"PeriodicalIF":2.5,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of health literacy-conscious medication educational videos on primary medication nonadherence rates 具有健康素养意识的用药教育视频对初级用药不依从率的影响。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-07 DOI: 10.1016/j.japh.2024.102219
Mel Nelson, Carlyn E. Vogel, Alexis Caronis, Joel Montavon, Patrick J. Campbell

Background

Primary medication nonadherence (PMN) occurs when a new medication is prescribed, but the patient does not obtain the medication, or an appropriate alternative. Medication knowledge may be a factor contributing to high PMN rates. A variety of approaches and technologies have been developed to enhance patient medication knowledge, though the impact of these interventions on PMN rates has not been studied.

Objectives

The objectives of this study were to: 1) compare community pharmacy PMN rates between pharmacies that offer patient medication educational video services and those that do not, and 2) assess the relationships between video service delivery and PMN status.

Methods

This cohort study utilized data from 6 pharmacies (3 case and 3 control). Adult individuals with a new electronic prescription for medications were assessed for PMN using the Pharmacy Quality Alliance measure specifications. A 6-month measurement period was used to assess if medications or an appropriate alternative were dispensed within 30 days. Descriptive statistics were used to evaluate differences in PMN rates between case and control pharmacies. The relationships between medication education video service use and PMN status were assessed using multivariable logistic regression models.

Results

A total of 4038 patients were included in the analyses, contributing 6311 prescriptions for PMN assessment. Case pharmacies had significantly lower (25.9% vs. 29.1%) PMN rates than control pharmacies (P = 0.0090). Prescriptions filled at pharmacies that utilized medication educational videos had lower odds of PMN status [odds ratio (OR) = 0.58 (0.43, 0.78)] than controls. Video use was associated with lower odds of PMN status [OR = 0.83 (0.70, 0.98)] when compared to prescriptions where patients did not receive the service.

Conclusions

The use of health literacy-conscious, patient educational videos were associated with improved (lower) PMN rates. Medication education technologies represent a scalable solution to improve PMN and medication access.
背景:初级用药不依从(PMN)是指开具了新药处方,但患者没有获得该药或适当的替代药物。用药知识可能是导致高PMN率的一个因素。目前已开发出多种方法和技术来提高患者的用药知识,但这些干预措施对 PMN 发生率的影响尚未得到研究:本研究的目的是1)比较提供与不提供患者用药教育视频服务的药房之间的社区药房 PMN 发生率;2)评估视频服务提供与 PMN 状态之间的关系:这项队列研究利用了六家药房(三家个案药房,三家对照药房)的数据。采用药房质量联盟 (PQA) 的测量规范,对新开具电子处方的成人进行 PMN 评估。以 6 个月为衡量周期,评估是否在 30 天内配发了药物或适当的替代品。描述性统计用于评估病例药房和对照药房之间 PMN 发生率的差异。使用多变量逻辑回归模型评估了用药教育视频服务的使用与 PMN 状态之间的关系:共有 4038 名患者被纳入分析,6311 张处方接受了 PMN 评估。病例药房的 PMN 感染率(25.9% 对 29.1%)明显低于对照药房(P=0.0090)。与对照药房相比,在使用药物教育视频的药房开具的处方出现 PMN 状态的几率[OR = 0.58 (0.43, 0.78)]更低。与未使用视频服务的处方相比,使用视频服务的处方出现 PMN 状态的几率更低[OR = 0.83 (0.70, 0.98)]:结论:使用注重健康素养的患者教育视频与 PMN 发生率的提高(降低)有关。用药教育技术是改善 PMN 和用药情况的一种可扩展解决方案。
{"title":"Impact of health literacy-conscious medication educational videos on primary medication nonadherence rates","authors":"Mel Nelson,&nbsp;Carlyn E. Vogel,&nbsp;Alexis Caronis,&nbsp;Joel Montavon,&nbsp;Patrick J. Campbell","doi":"10.1016/j.japh.2024.102219","DOIUrl":"10.1016/j.japh.2024.102219","url":null,"abstract":"<div><h3>Background</h3><div>Primary medication nonadherence (PMN) occurs when a new medication is prescribed, but the patient does not obtain the medication, or an appropriate alternative. Medication knowledge may be a factor contributing to high PMN rates. A variety of approaches and technologies have been developed to enhance patient medication knowledge, though the impact of these interventions on PMN rates has not been studied.</div></div><div><h3>Objectives</h3><div>The objectives of this study were to: 1) compare community pharmacy PMN rates between pharmacies that offer patient medication educational video services and those that do not, and 2) assess the relationships between video service delivery and PMN status.</div></div><div><h3>Methods</h3><div>This cohort study utilized data from 6 pharmacies (3 case and 3 control). Adult individuals with a new electronic prescription for medications were assessed for PMN using the Pharmacy Quality Alliance measure specifications. A 6-month measurement period was used to assess if medications or an appropriate alternative were dispensed within 30 days. Descriptive statistics were used to evaluate differences in PMN rates between case and control pharmacies. The relationships between medication education video service use and PMN status were assessed using multivariable logistic regression models.</div></div><div><h3>Results</h3><div>A total of 4038 patients were included in the analyses, contributing 6311 prescriptions for PMN assessment. Case pharmacies had significantly lower (25.9% vs. 29.1%) PMN rates than control pharmacies (<em>P</em> = 0.0090). Prescriptions filled at pharmacies that utilized medication educational videos had lower odds of PMN status [odds ratio (OR) = 0.58 (0.43, 0.78)] than controls. Video use was associated with lower odds of PMN status [OR = 0.83 (0.70, 0.98)] when compared to prescriptions where patients did not receive the service.</div></div><div><h3>Conclusions</h3><div>The use of health literacy-conscious, patient educational videos were associated with improved (lower) PMN rates. Medication education technologies represent a scalable solution to improve PMN and medication access.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"64 6","pages":"Article 102219"},"PeriodicalIF":2.5,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploration of network facilitator experiences implementing payer-partner programs within a nationwide clinically integrated network 探索网络促进者在全国临床综合网络内实施支付方合作伙伴计划的经验。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-06 DOI: 10.1016/j.japh.2024.102240
Jessica B. Finke, Cody Clifton, Laura A. Rhodes

Background

The Community Pharmacy Enhanced Services Network (CPESN) is a clinically integrated network (CIN) of approximately 3500 community-based pharmacies in 48 local networks across the United States. CPESN USA promotes expansion of innovative programs within community-based pharmacies including value-based contracting for patient care services. As opportunities grow, it is important to define strategies and tools needed to implement payer-partner programs.

Objective

This study aimed to explore strategies and resources used when implementing payer-partner programs within a CIN.

Methods

This cross-sectional electronic survey was e-mailed to 48 managing network facilitators (MNFs) representing 48 local CPESN networks across the United States. An electronic survey was e-mailed to the MNF of each local CPESN network. Fourteen questions collected the MNFs experience with (1) opportunities at the local network, (2) resources found helpful for implementing payer-partner programs, (3) barriers to implementing payer-partner programs, (4) confidence with tasks related to payer-partner program implementation, and (5) reporting what types of teammates they work with or manage when implementing a payer-partner program. The survey was open for data collection for 65 days. Data were analyzed using descriptive statistics.

Results

A total of 42 completed surveys were returned (response rate, 87.5%). MNFs ranked the barriers most frequently experienced as buy-in effect (n = 16, 41.0%) and management of pharmacy/network follow-through (n = 11, 28.2%). MNFs reported helpful resources for program implementation as peer-to-peer guidance (n = 31, 79.5%) and program handouts/guides (n = 30, 76.9%). MNFs reported additional resources needed as subject matter experts (n = 23, 59.0%) and templated communications (n = 22, 56.4%). MNFs expressed their highest levels of confidence in tasks related to leadership management (n = 30, 76.9%) and implementing programs (n = 28, 71.8%).

Conclusion

Barriers to payer-partner program implementation within the CIN were buy-in effect, management of pharmacy/network follow-through, management of peers, and management of pharmacy/network implementation. Leaders within the CIN reported desires for a toolkit that iterates successful strategies and education on building community and accountability within local networks. Development of tailored support and resources can enhance the capacity of network leaders to scale payer-partner programs within community-based pharmacies.
背景:社区药房强化服务网络 (CPESN) 是一个临床综合网络 (CIN),由全美 48 个地方网络中约 3,500 家社区药房组成。CPESN 美国促进了社区药房内创新计划的扩展,包括以价值为基础的患者护理服务合同。随着机会的增加,确定实施支付方合作伙伴计划所需的策略和工具非常重要:探索在 CIN 内实施支付方合作伙伴计划时所使用的策略和资源:通过电子邮件向代表全美 48 个 CPESN 地方网络的 48 个 MNF 发送了这份横向电子调查。电子调查表通过电子邮件发送给每个地方 CPESN 网络的 MNF。14 个问题收集了 MNF 在以下方面的经验:(1) 当地网络的机遇;(2) 认为对实施付款方合作伙伴计划有帮助的资源;(3) 实施付款方合作伙伴计划的障碍;(4) 对实施付款方合作伙伴计划相关任务的信心;(5) 报告在实施付款方合作伙伴计划时与哪些类型的队友合作或管理。调查的数据收集时间为 65 天。数据采用描述性统计进行分析:共收回 42 份完成的调查问卷(回复率为 87.5%)。医疗网络供应商认为最常遇到的障碍是 "买进效应"(16 人,41.0%)和 "药房/网络跟进管理"(11 人,28.2%)。移动网络家庭报告说,对计划实施有帮助的资源是同行指导(31 人,占 79.5%)和计划手册/指南(30 人,占 76.9%)。多国渔民报告说,他们还需要主题专家(人数=23,59.0%)和通信模板(人数=22,56.4%)。在与领导管理(30 人,76.9%)和实施计划(28 人,71.8%)相关的任务中,多国医疗保险基金表示他们的信心水平最高:在临床综合网络中,支付方合作伙伴计划实施的障碍是买入效应、药房/网络后续管理、同行管理以及药房/网络实施管理。临床整合网络的领导者表示,他们希望能有一个工具包,反复强调在当地网络内建立社区和问责制的成功策略和教育。开发有针对性的支持和资源可以提高网络领导者在社区药房内推广支付方合作伙伴计划的能力。
{"title":"Exploration of network facilitator experiences implementing payer-partner programs within a nationwide clinically integrated network","authors":"Jessica B. Finke,&nbsp;Cody Clifton,&nbsp;Laura A. Rhodes","doi":"10.1016/j.japh.2024.102240","DOIUrl":"10.1016/j.japh.2024.102240","url":null,"abstract":"<div><h3>Background</h3><div>The Community Pharmacy Enhanced Services Network (CPESN) is a clinically integrated network (CIN) of approximately 3500 community-based pharmacies in 48 local networks across the United States. CPESN USA promotes expansion of innovative programs within community-based pharmacies including value-based contracting for patient care services. As opportunities grow, it is important to define strategies and tools needed to implement payer-partner programs.</div></div><div><h3>Objective</h3><div>This study aimed to explore strategies and resources used when implementing payer-partner programs within a CIN.</div></div><div><h3>Methods</h3><div>This cross-sectional electronic survey was e-mailed to 48 managing network facilitators (MNFs) representing 48 local CPESN networks across the United States. An electronic survey was e-mailed to the MNF of each local CPESN network. Fourteen questions collected the MNFs experience with (1) opportunities at the local network, (2) resources found helpful for implementing payer-partner programs, (3) barriers to implementing payer-partner programs, (4) confidence with tasks related to payer-partner program implementation, and (5) reporting what types of teammates they work with or manage when implementing a payer-partner program. The survey was open for data collection for 65 days. Data were analyzed using descriptive statistics.</div></div><div><h3>Results</h3><div>A total of 42 completed surveys were returned (response rate, 87.5%). MNFs ranked the barriers most frequently experienced as buy-in effect (n = 16, 41.0%) and management of pharmacy/network follow-through (n = 11, 28.2%). MNFs reported helpful resources for program implementation as peer-to-peer guidance (n = 31, 79.5%) and program handouts/guides (n = 30, 76.9%). MNFs reported additional resources needed as subject matter experts (n = 23, 59.0%) and templated communications (n = 22, 56.4%). MNFs expressed their highest levels of confidence in tasks related to leadership management (n = 30, 76.9%) and implementing programs (n = 28, 71.8%).</div></div><div><h3>Conclusion</h3><div>Barriers to payer-partner program implementation within the CIN were buy-in effect, management of pharmacy/network follow-through, management of peers, and management of pharmacy/network implementation. Leaders within the CIN reported desires for a toolkit that iterates successful strategies and education on building community and accountability within local networks. Development of tailored support and resources can enhance the capacity of network leaders to scale payer-partner programs within community-based pharmacies.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"64 6","pages":"Article 102240"},"PeriodicalIF":2.5,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Student pharmacists lead the charge at 2024 APhA–ASP HoD 学生药剂师在 2024 年亚太药剂师协会-亚太药剂师协会主席会议上引领潮流
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-01 DOI: 10.1016/j.japh.2024.102206
Mark Nagel
{"title":"Student pharmacists lead the charge at 2024 APhA–ASP HoD","authors":"Mark Nagel","doi":"10.1016/j.japh.2024.102206","DOIUrl":"10.1016/j.japh.2024.102206","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"64 5","pages":"Article 102206"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The age of the machine is here … are you ready? 机器时代已经到来......你准备好了吗?
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-01 DOI: 10.1016/j.japh.2024.102209
Wendy Mobley-Bukstein
{"title":"The age of the machine is here … are you ready?","authors":"Wendy Mobley-Bukstein","doi":"10.1016/j.japh.2024.102209","DOIUrl":"10.1016/j.japh.2024.102209","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"64 5","pages":"Article 102209"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cover 封面
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-01 DOI: 10.1016/S1544-3191(24)00260-7
{"title":"Cover","authors":"","doi":"10.1016/S1544-3191(24)00260-7","DOIUrl":"10.1016/S1544-3191(24)00260-7","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"64 5","pages":"Article 102234"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tackling current events from the researchers’ perspective 从研究人员的角度处理时事问题
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-01 DOI: 10.1016/j.japh.2024.102205
Adriane N. Irwin
{"title":"Tackling current events from the researchers’ perspective","authors":"Adriane N. Irwin","doi":"10.1016/j.japh.2024.102205","DOIUrl":"10.1016/j.japh.2024.102205","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"64 5","pages":"Article 102205"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of the COVID-19 Pandemic on Employment Status Change for Practicing Pharmacists COVID-19 大流行对执业药剂师就业状况变化的影响。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-01 DOI: 10.1016/j.japh.2024.102187
David A. Mott, Vibhuti Arya, Brianne K. Bakken, William R. Doucette, Caroline Gaither, Aaron Gilson, David H. Kreling, Jon C. Schommer, Matthew Witry

Objective

The COVID-19 pandemic resulted in health care workers experiencing temporary or permanent changes in employment due to layoffs, quits, and postpandemic increased job demand. Analyzing the association of the COVID-19 pandemic with employment changes and results of changes for practicing pharmacists and understanding the associations with demographic and work-related factors could inform practice, policy, and educational programs. This study aimed to explore the frequency, characteristics, and results of employment status changes (ESCs) experienced by pharmacists practicing pharmacy in March 2020 (ie, the start of the COVID-19 pandemic).

Methods

A descriptive, cross-sectional survey research design was used to collect data from a random sample of 93,990 licensed pharmacists in the United States. The study team developed an online survey questionnaire designed to assess the impacts of the COVID-19 pandemic on pharmacists’ work and work-life. The survey items used for this study related to ESCs, work-life characteristics, work characteristics in March 2020 and 2022, and demographic variables. A total of 4947 usable responses were received between November 2022 and January 2023.

Results

Overall, 36.4% of respondents reported experiencing an ESC and approximately 70% of those reporting an ESC reported experiencing just 1 ECS. Overall, 39.5% of respondents who experienced an ESC stopped working (ie, were unemployed) pursuant to an ESC. Respondents who experienced an ESC reported significantly lower levels of work exhaustion and interprofessional disengagement and significantly higher levels of professional fulfillment in their current employment than respondents that did not experience an ESC.

Conclusion

The overall increase in demand for workers in the health care sector appeared to provide opportunities for pharmacists, especially pharmacists with 1 to 10 years of experience, to change their employment situation, resulting in better work-life characteristics. Given projections of a pharmacist shortage, research, policy, and educational programs could determine the best practices to improve work settings and the work-life characteristics of practicing pharmacists to improve the health of the current pharmacist workforce.
目标:COVID-19 大流行导致医护人员因裁员、辞职和大流行后工作需求增加而经历暂时或永久性的就业变化。分析 COVID-19 大流行与执业药剂师就业变化和变化结果的关联,并了解与人口和工作相关因素的关联,可为实践、政策和教育计划提供参考。本研究旨在探讨 2020 年 3 月(即 COVID-19 大流行的开始)执业药师经历的就业状况变化(ESC)的频率、特征和结果:采用描述性横断面调查研究设计,从美国 93,990 名执业药剂师中随机抽样收集数据。研究小组开发了一份在线调查问卷,旨在评估 COVID-19 大流行对药剂师工作和工作-生活的影响。本研究使用的调查项目涉及 ESC、工作-生活特征、2020 年 3 月和 2022 年 3 月的工作特征以及人口统计学变量。2022 年 11 月至 2023 年 1 月期间,共收到 4947 份可用回复:总体而言,36.4% 的受访者表示经历过一次 ESC,其中约 70% 的受访者表示只经历过一次 ESC。总体而言,39.5% 的经历过 ESC 的受访者因 ESC 而停止工作(即失业)。与没有经历过 ESC 的受访者相比,经历过 ESC 的受访者在当前工作中的工作疲惫程度和专业间脱离程度明显较低,专业成就感明显较高:医疗保健行业对员工需求的总体增长似乎为药剂师(尤其是拥有 1-10 年工作经验的药剂师)提供了改变就业状况的机会,从而改善了他们的工作-生活特性。鉴于药剂师短缺的预测,研究、政策和教育计划可以确定改善工作环境和执业药剂师工作-生活特点的最佳做法,以改善目前药剂师队伍的健康状况。
{"title":"Association of the COVID-19 Pandemic on Employment Status Change for Practicing Pharmacists","authors":"David A. Mott,&nbsp;Vibhuti Arya,&nbsp;Brianne K. Bakken,&nbsp;William R. Doucette,&nbsp;Caroline Gaither,&nbsp;Aaron Gilson,&nbsp;David H. Kreling,&nbsp;Jon C. Schommer,&nbsp;Matthew Witry","doi":"10.1016/j.japh.2024.102187","DOIUrl":"10.1016/j.japh.2024.102187","url":null,"abstract":"<div><h3>Objective</h3><div>The COVID-19 pandemic resulted in health care workers experiencing temporary or permanent changes in employment due to layoffs, quits, and postpandemic increased job demand. Analyzing the association of the COVID-19 pandemic with employment changes and results of changes for practicing pharmacists and understanding the associations with demographic and work-related factors could inform practice, policy, and educational programs. This study aimed to explore the frequency, characteristics, and results of employment status changes (ESCs) experienced by pharmacists practicing pharmacy in March 2020 (ie, the start of the COVID-19 pandemic).</div></div><div><h3>Methods</h3><div>A descriptive, cross-sectional survey research design was used to collect data from a random sample of 93,990 licensed pharmacists in the United States. The study team developed an online survey questionnaire designed to assess the impacts of the COVID-19 pandemic on pharmacists’ work and work-life. The survey items used for this study related to ESCs, work-life characteristics, work characteristics in March 2020 and 2022, and demographic variables. A total of 4947 usable responses were received between November 2022 and January 2023.</div></div><div><h3>Results</h3><div>Overall, 36.4% of respondents reported experiencing an ESC and approximately 70% of those reporting an ESC reported experiencing just 1 ECS. Overall, 39.5% of respondents who experienced an ESC stopped working (ie, were unemployed) pursuant to an ESC. Respondents who experienced an ESC reported significantly lower levels of work exhaustion and interprofessional disengagement and significantly higher levels of professional fulfillment in their current employment than respondents that did not experience an ESC.</div></div><div><h3>Conclusion</h3><div>The overall increase in demand for workers in the health care sector appeared to provide opportunities for pharmacists, especially pharmacists with 1 to 10 years of experience, to change their employment situation, resulting in better work-life characteristics. Given projections of a pharmacist shortage, research, policy, and educational programs could determine the best practices to improve work settings and the work-life characteristics of practicing pharmacists to improve the health of the current pharmacist workforce.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"64 5","pages":"Article 102187"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of the American Pharmacists Association
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1